About Ovensa

Ovensa Inc. is a Canadian, preclinical stage biotechnology company that capitalizes on its proprietary TRIOZAN™ Mucosal Delivery Platform to enhance the bioavailability and the targeted intracellular uptake of biologics and small molecules through various non-parenteral routes of administration.

Latest News

Montreal, January 12, 2015 – Aligo is proud to announce the granting of a worldwide exclusive license for all applications to Ovensa Inc. for the production and commercialization of trimethyl chitosan (TMC), a derivative of chitosan, a technology emanating from the University du Québec à Rimouski (UQAR).
View full press release...